Epstein-Barr virus-related primary central nervous system lymphoma after cadaveric renal transplantation improved by treatment with high-dose methotrexate followed by irradiation

Nephrology

Volumn 10, Issue 3, 2005, Pages 321-324

  Higuchi, Makoto ^a   Hata, Takenori ^a   Furuya, Shino ^a   Hosaka, Shigetoshi ^a   Kamijo, Yuji ^a   Kiyosawa, Kendo ^a   Ishizuka, Osamu ^a   Nishizawa, Osamu ^a   Hora, Kazuhiko ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epstein barr virus; High dose methotrexate; Irradiation; Primary CNS lymphoma; Renal transplantation

Indexed keywords

METHOTREXATE;

ADULT; APHASIA; ARTICLE; BRAIN TUMOR; CADAVER DONOR; CANCER RADIOTHERAPY; CASE REPORT; DRUG PULSE THERAPY; EPSTEIN BARR VIRUS; HEMODIALYSIS; HUMAN; IN SITU HYBRIDIZATION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; RECIPIENT;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; CADAVER; COMBINED MODALITY THERAPY; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; METHOTREXATE; POSTOPERATIVE COMPLICATIONS;

EID: 21344459307     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00398.x     Document Type: Article

References (18)

1. Swinnen LJ. Overview of posttransplant B-cell lymphoproliferative disorders. Semin. Oncol. 1999; 26: 21-5.
2. Ho M, Breinig MK, Dummer JS et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J. Infect. Dis. 1985; 152: 876.
3. Mutimer D, Kaur N, Tang H et al. Quantitation of Epstein-Barr virus DNA in the blood of adult liver transplant recipients. Transplantation 2000; 69: 954-9.
4. Swinnenn LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N. Engl. J. Med. 1990; 323: 1723-8.
5. Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989; 63: 939-47.
6. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 1992; 23: 9-17.
7. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system posttransplant lymphoproliferative disorders. Am. J. Clin. Pathol. 2004; 121: 246-253.
8. Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J. Clin. Oncol. 1998; 16: 3000-6.
9. Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-20.
10. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: The next step. J. Clin. Oncol. 2000; 18: 3144-50.
11. O'Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin. Oncol. 2000; 18: 519-26.
12. Wu HG, Kim IH, Ha SW, Park CI, Bang YJ, Huh DS. Survival improvement with combined radio-chemotherapy in the primary central nervous system lymphomas. J. Korean Med. Sci. 1999; 14: 565-70.
13. Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J. Clin. Oncol. 1998; 16: 864-71.
14. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 1998; 16: 859-63.
15. O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy? Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 663-73.
16. Blay JY, Bouhour D, Carrie C et al. The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. Blood 1995; 86: 2922-9.
17. Glass J, Gruber ML, Cher L et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J. Neurosurg. 1994; 81: 188-95.
18. DeAngelis LM, Yahalom J, Thaler HT et al. Combined modality therapy for primary CNS lymphoma. J. Clin. Oncol. 1992; 10: 635-43.